- Piramal Critical Care (PCC) is committed to reducing its environmental footprint and growing responsibly through sustainable operations
Piramal Pharma Ltd (PPL) Sustainability Report for FY21-22 articulates PPL's track record on ESG and the integration of sustainability practices across all its businesses, including PCC
MUMBAI, India, Nov. 17, 2022 /PRNewswire/ -- Piramal Critical Care (PCC) has integrated its sustainability framework into its strategy and daily business practices. As part of the effort, PCC's Environmental, Social and Governance (ESG) Policy encompasses environmentally friendly and sustainable practices in energy and waste management, climate change management, greenhouse gas reduction greenhouse gases (GHG), water management, supplier evaluation and the integration of sustainability into our operations to ensure the continuous improvement of our performance and employee engagement. PCC is the complex hospital generics business of Piramal Pharma Limited (PPL). PCC's commitment to sustainability aligns with the overall goal of integrating sustainable practices into all PPL businesses, as articulated in PPL's FY21-22 Sustainability Report.
Peter DeYoung, CEO, Global Pharma, said, "Our growth trajectory is guided by responsible business principles. Our second Sustainability Report is a manifestation of the progress of this trajectory and offers our stakeholders a transparent view of our performance in ESG matter."
Within the framework of the ESG strategy, one of the main areas of interest for Piramal are sustainability initiatives. We have set time-bound targets to review our energy and GHG emissions profile and develop a decarbonisation plan to reduce our Scope 1, 2 and 3 GHG emissions. We also strive to maximize green cover in our workplaces. The company is also taking initiatives to reduce energy consumption and manage energy systems through the implementation of energy efficient equipment and appliances, where appropriate. Water management, disposal of incinerable hazardous waste in landfills, and disposal of non-hazardous waste are also priority areas of the company's ESG plans. Our facilities use sustainable and environmentally friendly techniques.
Energy management is one of our main areas of interest due to its direct influence on emissions and the costs associated with our operations. We have implemented measures to improve the energy efficiency of our operations by improving processes, increasing the share of renewables, technology, absorbing and optimizing energy consumption from traditional sources. These interventions will help us reduce emissions and carbon footprint in the coming years.
climate change management
Our efforts and actions are continuously focused on reducing our scope 1 and 2 emissions. GHG emissions are generated mainly directly through the consumption of natural gas used to heat the facilities, create process steam and indirectly through the purchase of electricity. A closed manufacturing system coupled with an automated packaging line at our Bethlehem facility is designed to eliminate/reduce open handling. These measures contribute to addressing GHG emissions and minimizing negative ecological effects. We monitor and control the atmospheric emissions in our facilities, making sure that they are within the regulatory limits allowed according to the environmental permits of the place.
We are exploring new technologies and trying to develop water conservation solutions to reduce our use of fresh water. We plan to conduct a water use audit at all sites, which will allow us to identify areas to improve efficiency, reduce usage, and potential recycling options. During the 2021-22 fiscal year, total water use at our production sites was reduced by 8%.
All of our centers have adopted the 5R waste hierarchy (reduce, reuse, recycle, recover and rethink) for waste management in order to achieve a net reduction of waste. This approach is based on the principle that responsible waste management starts with reducing consumption whenever possible, so that less waste is generated. When waste reduction is not appropriate or feasible, disposal methods are considered, including direct waste-to-energy or those that offer methane generation credits.
Employee commitment to sustainability initiatives
We believe in instilling a sense of ownership among our employees. Our "Ideas to Excellence" (i2e) initiative encourages employees to share their ideas on innovative ways to improve and enhance our operations.
Main environmental aspects of the Sustainability Report of Piramal Pharma Ltd (PPL) for the year 21-22
Piramal Strategic ESG Framework
The framework has 12 focus areas, which guide PPL's strategic and operational imperatives. To view the company's ESG strategy, framework and goals, download the full report: PPL Sustainability Report FY21-22.
About Piramal Critical Care:
Piramal Critical Care (PCC) is a world leader in anesthesia, pain management and intrathecal therapy. PCC maintains an extensive presence in more than 100 countries, including the US and European markets. Our product portfolio includes inhalation anesthetics, injectable drugs for pain and anesthesia, anti-infectives, injectable drugs for myxedema coma, intrathecal therapy for the treatment of spasticity, and plasma volume expanders. Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, USA and Telangana, India, which are inspected by the US FDA, MHRA of the UK and other regulatory bodies, and partners with leading pharmaceutical development and manufacturing organizations around the world. For more information and updates visit: www.piramalcriticalcare.com
About Piramal Pharma Ltd.:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), a world-leading pharmaceutical company, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities at 15 global facilities and a distribution network global in more than 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a business of Complex Hospital Generics; and the India Consumer Healthcare business, which sells over-the-counter products. PPS offers comprehensive development and manufacturing solutions through a globally integrated network of facilities throughout the drug lifecycle for innovators and generic companies. PCC's complex portfolio of hospital products includes inhalation anesthetics, intrathecal therapies for the treatment of spasticity and pain, injectable analgesics and anesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is one of the major players in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received a strategic growth investment from the Carlyle Group.
For more information, visit: https://www.piramal.com/pharma/, Facebook, Twitter, LinkedIn
Photo: link Logo: link
View original content: enlace